Opioid Withdrawal Management using the Clinical Opiate Withdrawal Scale (COWS)
Introduction to COWS
- The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered assessment tool that objectively quantifies opioid withdrawal severity, primarily used to determine the appropriate timing and dosing of buprenorphine treatment, as recommended by the American Society of Addiction Medicine 1.
Structure and Scoring Components
- The COWS evaluates 11 specific withdrawal manifestations with weighted point values, including vital signs, autonomic symptoms, gastrointestinal distress, neuromuscular signs, psychological symptoms, and piloerection, as outlined in the Mayo Clinic Proceedings 1, 2.
- The COWS assesses vital signs, such as resting pulse rate, with a score of 0-4 points based on heart rate ranges 3.
- The COWS also evaluates autonomic symptoms, including sweating, pupil size, bone/joint aches, runny nose or tearing, with a score of 0-5 points 4.
Primary Clinical Application: Buprenorphine Induction
- COWS scoring directly determines when and how much buprenorphine to administer, with treatment initiated only when scores indicate moderate to severe withdrawal (COWS >8) to prevent precipitated withdrawal, as recommended by the American Society of Addiction Medicine 3.
- The initial dose of buprenorphine is 4-8 mg sublingual when COWS indicates moderate to severe withdrawal (>8) 3.
Role in Opioid Tapering
- During collaborative opioid dose reduction, COWS provides objective monitoring for emerging withdrawal symptoms, with withdrawal onset beginning 2-3 half-lives after last opioid dose 1.
- Peak symptoms occur at 48-72 hours, and resolution typically occurs within 7-14 days for acute withdrawal 6.
Pediatric Considerations
- While COWS was developed for adults, it can be adapted for children >7 days of opioid exposure requiring weaning protocols, as noted in Pediatrics 5, 8.
Practical Implementation
- Serial COWS assessments every 1-2 hours during buprenorphine induction allow real-time dose adjustments and early detection of precipitated withdrawal, which can then be managed symptomatically with clonidine, antiemetics, and benzodiazepines, as recommended by the American Society of Addiction Medicine 3, 7.